Afatinib is a tyrosine kinase inhibitor for managing non–small cell lung carcinoma (NSCLC). Afatinib is designed to cause irreversible inhibition of the ErbB family of tyrosine kinases. The FDA has approved afatinib for treating locally advanced or metastatic NSCLC characterized by nonresistant epidermal growth factor receptor (EGFR) mutations. Additionally, it is a second-line option for advanced squamous NSCLC. Beyond these applications, afatinib is being investigated as a monotherapy for individuals with HER2-positive breast cancer who have experienced progression despite management with trastuzumab. This activity aims to familiarize healthcare providers with afatinib's approved indications and mechanism of action while addressing potential adverse reactions and highlighting considerations regarding toxicity.
Copyright © 2026, StatPearls Publishing LLC.